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Abstract
Chronic treatment with olanzapine causes desensitization of serotonin2A receptor signaling. The
purpose of the current study is to further understand the mechanisms underlying this desensitization
response of serotonin2A receptor signaling in vivo. We now report that desensitization of
serotonin2A receptor stimulated-phospholipase C activity in rat frontal cortex induced by olanzapine
is dependent on activation of the JAK-STAT pathway. Olanzapine treatment for 7 days significantly
increased the levels of the regulator of G protein signaling (RGS7) protein, RGS7 mRNA levels, and
activation of JAK2 in rat frontal cortex. Pretreatment with a JAK2 inhibitor AG490, significantly
attenuated the olanzapine-induced reductions in serotonin2A receptor-stimulated phospholipase C
activity and prevented the olanzapine-induced increases in RGS7 mRNA and protein levels. In
contrast, inhibition of the JAK-STAT pathway with AG490 did not reverse the olanzapine-induced
desensitization of the serotonin2A receptor pathway in the hypothalamic paraventricular nucleus
mediating increases in plasma hormone levels. AG490 dose-dependently inhibited serotonin2A
receptor-stimulated oxytocin and corticosterone release. Taken together, these results suggest that
the olanzapine-induced increase in RGS7 expression is mediated by activation of JAK-STAT and is
necessary for olanzapine-induced desensitization of serotonin2A receptor-stimulated phospholipase
C activity in the frontal cortex but not serotonin2A receptor-stimulated hormone release.
Introduction
Serotonin 2A (5-HT2A) receptors are involved in a number of psychiatric disorders, including
schizophrenia, depression, and anxiety (Nichols, et al., 1994;Naughton, et al., 2000).
Furthermore, atypical antipsychotics are reported to bind with high affinity at 5-HT2A receptors
as determined in cell culture and in vivo (Zhang and Bymaster, 1999). Although atypical
antipsychotics bind to diverse population of receptors (Roth, et al., 2004;Zhang and Bymaster,
1999), the therapeutic benefits associated with atypical antipsychotics are attributed, in part,
to their ability to antagonize (i.e. desensitize) 5-HT2A receptor signaling (Goyer, et al.,
1996). Further evidence for the involvement of 5-HT2A receptors in the mechanisms of action
of atypical antipsychotics comes from reports of polymorphisms in the promoter and coding
regions of the 5-HT2A receptor gene. Schizophrenics with this polymorphism are reported to
respond poorly to clozapine treatment suggesting that genetic variation at 5-HT2A receptors
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may influence clozapine response and strengthens the candidacy of these receptors as important
therapeutic targets (Yu, et al., 2001;Arranz, et al., 1996;Masellis, et al., 1998). By determining
the mechanisms by which atypical antipsychotics desensitize 5-HT2A receptor signaling, we
may uncover new targets for drug manipulation.
Atypical antipsychotics reduce the levels of ACTH and cortisol in schizophrenic patients
(Cohrs, et al., 2006;Hatzimanolis, et al., 1998;Scheepers, et al., 2001b), an effect that would
be mediated by antagonism of 5-HT2A receptors in hypothalamic neuroendocrine cells.
Although, monoaminergic mechanisms including serotonin and dopamine are known to play
an important role in the regulation of ACTH and cortisol secretion (Wilcox, et al., 1975;Fuller
and Snoddy, 1984;Tuomisto and Mannisto, 1985;Lefebvre, et al., 1998), the attenuation of
cortisol secretion, after subchronic administration of olanzapine and clozapine to schizophrenic
patients, has been attributed to 5-HT receptor blockade (Hatzimanolis et al., 1998). In fact, we
previously demonstrated that 5-HT2A receptors in the hypothalamic paraventricular nucleus
(PVN) mediate the neuroendocrine responses to a peripheral injection of the 5-HT2A/2C
receptor agonist (-)-1-(2,5-dimethoxy-4-iodophenyl)2-aminopropane (DOI); intra-PVN and
peripheral injections of the selective 5-HT2A receptor antagonist MDL 100,907 dose-
dependently inhibit the DOI-induced increases in hormone secretions (Zhang et al., 2002).
Several studies demonstrate that chronic administration of atypical antipsychotics causes the
desensitization and down-regulation of central 5-HT2A receptor signaling (Blackshear and
Sanders-Bush, 1982), however, the molecular mechanisms underlying these changes are not
understood. 5-HT2A receptors are coupled through Gq/11 proteins to phospholipase C (PLC)
(Roth, et al., 1998). Upon activation of PLC, hydrolysis of phosphatidylinositol 4,5-
bisphosphate generates diacylglycerol and inositol 1,4,5-trisphosphate. Gαq/11 proteins
stimulate PLC activity until the bound GTP is hydrolyzed to GDP. The intrinsic GTPase
activity of Gαq/11 proteins is enhanced by regulators of G protein signaling proteins type 4 and
7 (RGS4 and RGS7) (Xu, et al., 1999).
Activation of 5-HT2A receptors also activates the JAK-STAT pathway. Although, the exact
mechanism by which 5-HT2A receptors activate the JAK-STAT pathway is not known, 5-
HT2A receptors associate with JAK and STAT and rapid activation of JAK and STAT via
phosphorylation in response to serotonin was previously reported (Guillet-Deniau, et al.,
1997). We previously reported that daily treatment of rats with olanzapine for 7 days causes
desensitization of 5-HT2A receptor signaling accompanied by activation of STAT3 and
increases in RGS7 protein levels (Muma, et al., 2007). The JAK-STAT pathway regulates
expression of a number of transcription factors including c-Fos, c-Jun and c-Myc (Burysek, et
al., 2002;Cattaneo, et al., 1999) which can then stimulate expression of select genes. Consistent
with these reports, olanzapine treatment in cell culture increases phospho-STAT binding to the
putative promoter region of RGS7, increases RGS7 mRNA levels and membrane-associated
RGS7 protein levels and causes JAK-STAT dependent desensitization (Singh et al., 2007;
Singh, et al., in press). We hypothesize that the increased membrane-associated RGS7 protein
can then increase hydrolysis of activated Gαq/11 and contribute to the desensitization of 5-
HT2A receptor signaling. However, whether olanzapine-induced activation of the JAK-STAT
pathway has any direct impact on desensitization of 5-HT2A receptor signaling in vivo is
currently unknown.
Here, we investigate the impact of blocking the JAK-STAT pathway with a specific JAK2
inhibitor, AG490, on olanzapine-induced desensitization of 5-HT2A receptor signaling in the
frontal cortex via measurements of PLC activity and in the PVN via hormone release.
Furthermore, we also monitored the effect of AG490 on olanzapine-induced increases in RGS7
protein levels in PVN and the levels of RGS7 mRNA and protein in the frontal cortex.
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Male Sprague-Dawley rats (250–275 g; Harlan, Indianapolis, IN) were housed two per cage
in an environment controlled for temperature, humidity, and lighting (7:00 AM–7:00 PM).
Food and water were provided ad libitum. Eight rats were used per experimental group. All
procedures were conducted in accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals as approved by the Loyola University Institutional Animal
Care and Use Committee.
Drugs
Olanzapine and AG490 were purchased from Toronto Research Chemicals Inc., (ON, Canada).
Olanzapine was dissolved in 20% glacial acetic acid and the pH was adjusted to 6.0 with 10M
NaOH as described previously (Singh et al., 2007). Olanzapine was injected at a dose of 10
mg/kg i.p. AG490 was dissolved in 50% DMSO and injected at 2 mg/kg or 10 mg/kg s.c. DOI
was purchased from Sigma/RBI (Natick, MA) and dissolved in 0.9% saline and injected at a
dose of 1 mg/kg s.c. for the challenge injections.
Experimental procedures
Rats were randomly assigned to the experimental groups with cage mates being placed within
the same experimental groups. The body weight of each rat was recorded every alternate day.
They were kept in a quiet environment and handled for several days to minimize stress. Once
a day for seven days, rats were first injected with vehicle (50% DMSO s.c.) or one dose of
AG490 (2 mg/kg or 10 mg/kg s.c.). One hr later these rats were injected with either the vehicle
(20% glacial acetic acid, i.p.) or 10 mg/kg olanzapine (i.p.). Twenty-four hr after the last
injection of vehicle or olanzapine, eight rats from each group received either a challenge
injection of DOI (1 mg/kg s.c.) or a 0.9% saline (1 ml/kg s.c.) and were sacrifice 30 min later.
The trunk blood was collected in centrifuge tubes containing 0.5 ml of 0.3 M EDTA (pH 7.4)
solution. The plasma samples for radioimmunoassays were stored at −80°C. Whole brains were
removed, frozen and stored at −80°C for biochemical and molecular analyses.
PLC activity assay
The membrane fraction prepared from frontal cortex of animals challenged with saline was
used for the measurement of PLC activity. The PLC activity assay was performed as described
previously (Damjanoska, et al., 2004). Briefly, 30 µg of membrane protein from frontal cortex
was diluted into 100 µl of total volume with a buffer containing 25 mM Hepes-Tris, 3 mM
EGTA, 10 mM LiCl, 12 mM MgCl2, 1.44 mM sodium deoxycholate with 1 µM GTPγS, 300
nM free Ca2+, 1 µM 5-HT, and 1 mM unlabeled phosphatidyl inositol. The reaction tubes were
kept on ice until the incubation period (20 min at 37°C) was started with the addition of 100
µM [3H] phosphatidyl inositol. The reaction was stopped by addition of 0.9 ml of CHCl2/
MeOH (1:2) and 0.3 ml of chloroform. The tubes were shaken vigorously for 90 seconds and
centrifuged at room temperature for 90 seconds at 13,600 × g. Then, 0.3 ml of the upper aqueous
phase was mixed with 4 ml of scintillation cocktail and counted by a scintillation counter for
5 min. Protein concentrations in these membrane preparations were measured using the
bicinchoninic acid protein assay kit (Pierce Chemical, Rockford, IL).
Radioimmunoassay of hormones
Plasma concentrations of oxytocin, ACTH, and corticosterone were determined by
radioimmunoassay as described previously (Li, et al., 1993). We used this assay to measure
the activity of 5-HT2A receptors in the PVN because we previously demonstrated that activation
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of 5-HT2A receptors in this hypothalamic nucleus stimulates the release on oxytocin, ACTH
and corticosterone (Zhang, et al., 2002).
Immunoblot analyses of RGS7, pJAK2, and JAK2 proteins
Tissue preparation—Frontal cortex and PVN from the treatment groups that received 1
mg/kg DOI injection were used for the measurement of pJAK2, JAK2 and RGS7 proteins. The
PVN was dissected from a 700 µm coronal brain section obtained using a cryostat (−10°C) as
previously described. Tissue was homogenized in 20 volume of ice-cold homogenization
buffer which contained 25 mM HEPES-Tris, pH 7.4 at 25 °C, 1 mM EGTA and protease
inhibitor cocktail (1:1000) from Sigma-Aldrich (St. Louis, MO) by using a Tekmar Tissumizer
(Cincinnati, OH). The homogenate was centrifuged at 20,000 × g for 10 minutes at 4°C. After
centrifugation, the supernatant was collected as the cytosolic fraction. The tissue pellet was
resuspended in 20 volumes homogenization buffer and centrifuged again. The final membrane
pellet was resuspended and sonicated in 25 mM HEPES-Tris buffer containing 3 mM EGTA
and 10 mM LiCl. Protein concentrations were determined by using a bicinchoninic acid protein
assay kit (Pierce Chemical, Rockford, IL).
Western blot analyses—Equal amounts of protein from vehicle-control and drug-treated
samples were separated on 10% SDS polyacrylamide gels. Non-specific binding was blocked
either in Tris-buffered saline (TBS) containing 5% (w/v) nonfat dry milk with 0.1% Tween 20
(TBST) or in phosphate buffered saline (PBS) containing 5% (w/v) nonfat dry milk. The
following primary antibodies were used: anti-RGS7 (polyclonal antibody, Upstate
Biotechnology, Inc., Lake Placid, NY), anti-phospho-JAK2 (polyclonal antibody, Affinity
Bioreagent, CO), anti-JAK2 (polyclonal antibody, Upstate Biotechnology, Inc., Lake Placid,
NY) and anti-actin (monoclonal antibody MP Biomedicals, Aurora, OH). Prior to incubation
with a second primary antibody, blots were stripped with Restore western blot stripping buffer
(Pierce, Rockford, IL) by incubating at 37°C for 25 minutes. After incubation, blots were
removed from stripping buffer, washed three times for 10 minutes each with TBS or PBS
containing 0.1% Tween20 (TBST or PBST) and blocked with 5% milk in TBST or PBST for
1 hr at room temperature. Protein bands were analyzed densitometrically using Scion Image
software (Scion Corporation, Frederick, MD). The gray scale density readings were calibrated
using a transmission step-wedge standard. The integrated optical density (IOD) of each band
was calculated as the sum of the optical densities of all the pixels within the area of the band
outlined. The IOD for the film background was subtracted from the IOD for each band. Each
sample was measured in triplicate. RGS7 protein was normalized to actin protein and
phosphoproteins were normalized to the corresponding total protein levels. Protein levels from
treated groups were normalized to vehicle-treated groups for each western blot analysis.
RNA Isolation and Reverse Transcription
Total RNA was isolated using the RNeasy Mini Kit (Qiagen Sciences, Valencia, CA) according
to the manufacturer’s protocol. Total RNA was quantitated using a spectrophotometer and
optical density ratios at 260/280 nm were determined. Quality of RNA was further assessed
on a formaldehyde-agarose gel. First strand cDNA was synthesized using random hexamers
and Superscript II Reverse Transcriptase from Invitrogen (Carlsbad, CA) according to the
manufacturer’s protocol.
Real-Time PCR
The GAPDH (sense 5’-tggagtctactggcgtcttcac-3’; antisense 5’- ggcatggactgtggt catga-3’) and
RGS7 (sense 5’-gaagatgagttgcaccgacaga-3’; antisense 5’-ggtctttcagtgcct catccat-3’) primer
sets were synthesized by IDT, Inc (Coralville, IA). PCR amplification was performed with
7500 Real-Time PCR System using SYBR green PCR master mix (Applied Biosystems, Foster
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City, CA). The PCR parameters used were a 10 minute denaturation cycle at 95°C, 40 cycles
of amplification at 95°C for 15 seconds, and annealing/extension at 60°C for 1 minute. Real-
Time PCR was performed with 25 µL reaction mixture of cDNA, primers and SYBR green
master mix.
RNA Data Analysis
Comparative Ct (ΔΔCT) method was used for analysis of all real-time PCR data. ΔCT values
were calculated by normalizing CT values of RGS7 to GAPDH from vehicle and drug-treated
animal groups. The extent of the response is determined by 2mean(ΔΔCT), and the relative degree
of response is calculated by 2−mean (ΔΔCT). Results are expressed as fold change in RGS7
mRNA levels for AG490, olanzapine, AG490 and olanzapine-treated cells with respect to
vehicle-treated cells. Data presented are from four independent experiments performed in
triplicate.
Statistical analyses
All statistical analyses were performed using GB-STAT School Pak (Dynamic Microsystems,
Silver Spring, MD). Data are expressed as means ± SEM. RT-PCR, western blot data, and the
PLC activity assays were analyzed using a two-way analysis of variance, followed by a
Newman–Keuls' post hoc analysis. Hormone levels were analyzed using a three-way analysis
of variance, followed by Newman-Keuls’ post hoc analysis. RGS7 and phospho-JAK2 levels
in the PVN of rats treated with 10 mg/kg olanzapine were compared to vehicle-treated controls
using a Student's t-test.
Results
Phosphorylation of JAK2 in frontal cortex was blocked by AG490 treatment
To verify that the JAK-STAT signaling pathway in frontal cortex is stimulated treatment with
olanzapine as previously demonstrate (Muma et al., 2007), we first measured the
phosphorylation of JAK2. Treatment with olanzapine for 7 days significantly increased
(*p<0.05) phosphorylation of JAK2 in the membrane fraction of the frontal cortex as shown
in figure 1. The total JAK2 protein level was not significantly altered with olanzapine treatment.
Next, we determined whether the JAK2 inhibitor AG490 indeed inhibited JAK2 activation via
phosphorylation. The olanzapine-induced increases in phosphorylation of JAK2 were
significantly reduced to basal levels by pre-injections of AG490 at 10 mg/kg. As a control, we
also measured the effects of treatment with AG490 alone and found that AG490 alone had no
effect on JAK2 phosphorylation. Two way ANOVA indicates a main effect of olanzapine
(F(1,15) = 19.88, p < 0.001), a main effect of AG490 (F(1,15) = 37.41, p < 0.001), and a significant
interaction between olanzapine and AG490 was also observed (F(1,15) = 31.28, p = 0.001).
Inhibition of the JAK-STAT pathway attenuated the olanzapine-induced inhibition of 5-
HT2A receptor-mediated PLC activity in frontal cortex
We previously reported that olanzapine treatment for 7 days caused a significant decrease in
5-HT-stimulated PLC activity in the rat frontal cortex (Muma et al., 2007). Consistent with
our previous report, in the current study, 10mg/kg olanzapine treatment for 7 days caused a
68% decrease (*p<0.01) in 5-HT-stimulated PLC activity in the frontal cortex (Figure 2A). As
a control, PLC activity was examined in rats treated with AG490 alone; PLC activity was not
affected by AG490 treatment alone. However, the decrease in 5-HT-stimulated PLC activity
induced by olanzapine was significantly attenuated (*p<0.05) in rats injected with AG490 and
olanzapine at 10 mg/kg compared to rats injected with vehicle and olanzapine, suggesting that
the olanzapine-induced desensitization of PLC activity in rat frontal cortex is dependent on
activation of the JAK2-STAT3 pathway. Two-way ANOVA indicates a main effect of
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olanzapine (F(1,19) = 5.91, p<0.05), a main effect of AG490 (F(1,19) = 46.18, p<0.001), but no
significant interaction was observed between olanzapine and AG490 (F(1,19) = 1.27, p=.275).
Furthermore, AG490 or olanzapine treatment had no effect (p> 0.05) on GTPγS-stimulated
PLC activity (Figure 2B).
Olanzapine-induced increases in RGS7 mRNA and protein levels in frontal cortex were
blocked by pre-treatment with AG490
Our previous studies demonstrated that olanzapine treatment increases RGS7 protein levels in
rat frontal cortex (Muma et al., 2007) and that the olanzapine-induced increases RGS7 protein
and mRNA levels in cells in culture are dependent on activation of the JAK2-STAT3 pathway
(Singh et al., in press). We now wanted to determine if RGS7 mRNA levels are increased in
rat frontal cortex and if the increases in RGS7 protein and mRNA are dependent on activation
of the JAK2-STAT3 pathway. Olanzapine injections for 7 days significantly increased mRNA
(*p<0.05) and protein (*p<0.05) levels of RGS7 as shown in Figure 3A and 3B. To control for
the effects of AG490, we examined the effects of AG490 alone on RGS7 expression. Both
mRNA and protein levels of RGS7 were not affected by AG490 treatment alone. However, in
rats pre-injected with AG490 at 10 mg/kg, the olanzapine-induced increases in RGS7
expression were significantly attenuated to basal levels. Two-way ANOVA for mRNA
measurement indicates a main effect of olanzapine (F(1,15)=43.43, P<0.001), a main effect of
AG490 (F(1,15)=155.96, P<0.001), and a significant interaction between olanzapine and
AG490 (F(1,15)=69.51, P<0.001). Two-way ANOVA for protein levels indicate a main effect
of olanzapine (F(1,15)=10.30, P<0.01), a main effect of AG490 (F(1,15)=12.30, P<0.01), and a
significant interaction between olanzapine and AG490 (F(1,15)=12.40, P<0.01). These results
suggest that the increased expression of RGS7 induced by olanzapine is dependent on the
JAK2-STAT3 pathway in rat frontal cortex as in cells in culture.
Olanzapine-induced desensitization of 5-HT2A receptor signaling in PVN was not reduced by
AG490
Basal plasma ACTH, corticosterone, and oxytocin levels were not significantly altered after
seven daily injections of AG490 and olanzapine. DOI-challenge produced a significant
(*p<0.01) increase (1,257%) in plasma oxytocin levels in vehicle-pretreated rats, in 2 mg/kg
AG490 pre-treated rats (853%, *p<0.01), and in 10 mg/kg AG490 pre-treated rats (449%,
*p<0.01) compared to saline-challenged rats. However, AG490 -pretreatment produced a dose-
dependent inhibition of oxytocin release in rats. Olanzapine treatment completely blocked the
DOI-induced increases in oxytocin release as compared to vehicle-treated rats (Figure 4A).
Although, a trend towards reversal of the olanzapine-inhibited oxytocin level was observed at
the high dose of AG490 (10 mg/kg), it was not statistically significant. Three-way ANOVA
indicates a main effect of DOI challenge on oxytocin levels (F(1,81)= 44.62, P<0.0001), a main
effect of olanzapine (F(1,81)= 5.36, P<0.05), and a main effect of AG490 (F(2,81)= 9.94,
P<0.001). Significant interactions between DOI and olanzapine (F(1,81)= 28.12, P<0.0001),
DOI and AG490 (F(2,81)= 63.57, P<0.0001), and olanzapine and AG490 (F(2,81)= 165.69,
P<0.0001) were also observed. Finally, there was significant interaction among DOI,
olanzapine and AG490 (F(2,81)= 65.83, P<0.0001).
ACTH response to DOI—A DOI-challenge produced a significant (*p<0.01) increase in
plasma ACTH levels in vehicle-pretreated rats (1279%) and in 2 mg/kg AG490-pretreated rats
(1296%) (*p<0.01), and in 10 mg/kg AG490 injected rats (1032%) (*p<0.01) compared to
saline-challenged rats (Fig.4B). Olanzapine treatment significantly (38%,*p<0.01) attenuated
the DOI-stimulated increase in ACTH release as compared to vehicle treated rats (Figure 4B).
However, AG490 treatment had no significant effect on ACTH levels in rats treated with
olanzapine compared to the respective vehicle-treated rats. Three-way ANOVA indicates a
main effect of DOI challenge on ACTH levels (F(1,66)= 118.44, and a main effect of AG490
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(F(2,66)= 22.32, P<0.0001). A significant interaction between DOI and olanzapine (F(1,66)=
16.46, P<0.001), DOI and AG490 (F(2,66)= 99.68, P<0.0001), and olanzapine and AG490
(F(2,66)= 1897.87, P<0.0001) was also observed. There was also a significant interaction among
DOI and olanzapine and AG490 (F(2,66)= 155.32, P<0.0001).
Corticosterone response to DOI—DOI-challenge produced a significant (*p<0.01)
increase in plasma corticosterone levels in vehicle-pretreated rats (685%) and in 2 mg/kg
AG490-pretreated rats (524%) (*p<0.01), and in 10 mg/kg AG490 injected rats (406%)
(*p<0.01) compared to saline-challenged rats (Fig.4C). Olanzapine treatment significantly
(54%,*p<0.01) attenuated the DOI-stimulated increase in corticosterone release as compared
to vehicle-treated rats (Figure 4C). However, AG490 pretreatment had no significant effect on
corticosterone levels in rats treated with olanzapine. Three-way ANOVA indicates a main
effect of DOI challenge on corticosterone (F(1,82)= 43.57, P<0.0001), a main effect of
olanzapine (F(1,82)= 5.96, P<0.001), a main effect of AG490 (F(2,82)= 10.55, P<0.0001). A
significant interaction between DOI and olanzapine (F(1,82)= 29.63, P<0.001), DOI and AG490
(F(2,82)= 62.98, P<0.0001), and olanzapine and AG490 (F(2,82)= 164.50, P<0.0001) was also
observed. Finally, there was a significant interaction between DOI, olanzapine and AG490
(F(2,82)= 68.01, P<0.0001).
Olanzapine increased JAK2 phosphorylation in the PVN
Olanzapine treatment (10 mg/kg, for 7 days) significantly (p<0.01) increased (184 ± 11.9% of
control levels) the membrane-associated levels of phosphorylated JAK2 in the PVN (Fig. 5).
As shown in Fig 5, total JAK2 protein levels in the PVN were not altered by chronic olanzapine
treatment.
Olanzapine increased RGS7 protein levels in the PVN
As shown in Fig 6, membrane-associated RGS7 protein levels in the PVN in olanzapine treated
rats were significantly increased to over twice (208 ± 19.2% of control levels) the levels in
vehicle treated rats (t = − 7.9, p < 0.0001). Actin was used as a loading control.
Discussion
Although, atypical antipsychotics bind to a number of different neurotransmitter receptors
(Zhang and Bymaster, 1999;Roth et al., 2004), their therapeutic benefits are attributed, in part,
to their ability to desensitize 5-HT2A receptor signaling (Goyer et al., 1996). Previous studies
have shown that atypical antipsychotics induced desensitization of 5-HT2A receptor signaling
both in vivo and in cells (Gray and Roth, 2001;Hanley and Hensler, 2002). Internalization and
down-regulation of 5-HT2A receptors are suggested to be involved in the desensitization
response; however, the underlying molecular mechanisms necessary for desensitization are not
yet identified. Previously, we reported that both in rat frontal cortex and in cell culture,
olanzapine causes desensitization of 5-HT2A receptor-stimulated PLC signaling, increases
RGS7 protein expression and activates the JAK-STAT pathway (Muma, et al., 2007;Singh, et
al., 2007). Furthermore, we found that in A1A1v cells JAK-STAT signaling is necessary for
approximately half of the desensitization response (Singh et al., in press).
Consistent with our previous findings in cultured A1A1v cells, we now find that the olanzapine-
induced desensitization of 5-HT2A receptor-mediated PLC activity in the rat frontal cortex is
dependent on activation of the JAK-STAT signaling pathway. Indeed, AG490-pretreatment
that inhibited the olanzapine-induced activation of JAK2 in frontal cortex, prevented the
olanzapine-induced desensitization of 5-HT2A receptor signaling and attenuated the
olanzapine-induced increases in RGS7 mRNA and protein levels in frontal cortex. We
previously reported that increased RGS7 protein expression in response to olanzapine treatment
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is dependent on JAK-STAT signaling in A1A1v cells (Singh et al., 2007). The current data
suggest that activation of the JAK-STAT pathway is necessary for the complete olanzapine-
induced desensitization of 5-HT2A receptor signaling in frontal cortex as well.
RGS proteins can reduce G-protein-mediated signaling by their ability to increase the intrinsic
guanosine triphosphatase (GTPase) activity of heterotrimeric G proteins or by blocking the
interaction of Gα proteins with effectors. The GTPase accelerating protein (GAP) activity
enhances G protein deactivation and promotes desensitization (Dohlman and Thorner, 1997).
An increase in RGS7 protein following olanzapine treatment would increase the termination
rate of 5-HT2A receptor-Gαq/11 protein signaling by more rapidly hydrolyzing GTP, and could
thereby produce or contribute to the desensitization response.
Previous studies have reported down-regulation of RGS4 expression in the frontal cortex of
schizophrenic patients (Mirnics et al., 2001; Gu et al., 2007). However, none of these studies
have identified alterations in RGS7 expression. The olanzapine-induced increase in RGS7
protein might replace the diminished RGS4 levels and thereby restore the 5-HT2A receptor
signaling duration to more physiological levels.
The olanzapine-induced increase in RGS7 levels could be mediated by either increased stability
of RGS7 proteins and/or increased transcription of RGS7 mRNA. Our real-time PCR data
suggests that the increase in RGS7 levels by olanzapine is mediated by a direct increase in
RGS7 mRNA via activation of JAK-STAT pathway. In our previous studies, we identified a
STAT3 consensus binding element located 2.34kb upstream of transcription start site that binds
strongly with STAT3 in response to olanzapine treatment (Singh et al., in press). Thus, STAT3
binding to the RGS7 gene, along with an increase in mRNA levels of RGS7 suggest the
possibility that STAT3 could be a transcription factor for RGS7. Taken together, these results
are consistent with our hypothesis that atypical antipsychotics increase RGS7 expression via
activation of the JAK-STAT pathway.
Alternatively, interaction of RGS7 with Gβ5 (Zhang and Simonds, 2000) is reported to increase
the stability of RGS7. In addition, interaction of RGS7 with 14–3–3 is reported to control its
GAP activity (Benzing, et al., 2000). Previous reports have suggested that activation of JAK-
STAT by tumor necrosis factor α (TNFα) (Guo, et al., 1998) decreases the inhibitory interaction
of RGS7 with 14–3–3 thereby increasing its GAP function (Benzing, et al., 2002). Thus, it is
possible that activation of JAK-STAT pathway by olanzapine treatment could increase GAP
activity of RGS7 by inhibiting its interaction with 14–3–3, or increasing the stability of RGS7
protein and could mediate, at least in part, the olanzapine-induced regulation of RGS7 GAP
activity.
While the precise mechanism of JAK-STAT activation by atypical antipsychotics is not
determined, it has been reported that the 5-HT2A receptor associates in a complex with JAK2
and STAT3 (Guillet-Deniau et al., 1997). Other studies have reported that 5-HT activates
JAK2, JAK1, and STAT1 via the 5-HT2A receptors (Banes, et al., 2005). Furthermore, atypical
antipsychotics have also been reported to activate other signaling cascades, for example,
activation of ERK1/2 pathways in the rat frontal cortex (Fumagalli, et al., 2006), and Akt/PKB
and P38 pathways in PC12 cells (Lu, et al., 2004). It is becoming evident that there could be
numerous pathways and alterations in gene expression that lead to the development of
psychosis and its treatment with atypical antipsychotics. We found almost 50% attenuation of
the olanzapine-induced reductions in PLC activity in the frontal cortex with inhibition of the
JAK-STAT pathway, suggesting one of these other signaling cascades together with the JAK-
STAT pathway could participate in mediating desensitization of 5-HT2A receptor signaling by
atypical antipsychotics. Similarly, we previously found that inhibition of the JAK-STAT
pathway reduced by the olanzapine-induced desensitization response by approximately half in
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A1A1v cells. These results produced by inhibition of the JAK-STAT pathway suggest that
activation of the JAK-STAT pathway is necessary but not sufficient to induce complete
desensitization of 5-HT2A receptor signaling by atypical antipsychotics and may involve other
signaling cascades.
A wide range of studies have suggested a link between hypothalamic-pituitary-adrenal (HPA)-
axis dysfunction and psychiatric disorders particularly the negative symptomatology in
schizophrenia (Shirayama, et al., 2002;Walker, et al., 2002). Studies have also demonstrated
that the atypical antipsychotic-induced decrease in cortisol levels is associated with an
improvement in psychopathology (Hatzimanolis, et al., 1998)(Markianos, et al., 2001). The
olanzapine-induced decrease in plasma levels of oxytocin, ACTH, and corticosterone in this
study are consistent with previous reports (Scheepers, et al., 2001a;Tepavcevic, et al., 1994)
and suggest that chronic olanzapine-treatment produced a functional desensitization of 5-
HT2A receptors in PVN as well. However, unlike in the frontal cortex where preinjections of
AG490 significantly attenuated the olanzapine-induced decrease in 5-HT2A receptor-mediated
PLC activity, olanzapine-induced desensitization of 5-HT2A receptor stimulated plasma
hormone release was not affected by inhibition of JAK-STAT signaling pathway.
Unfortunately, we are not able to measure 5-HT2A receptor-stimulated PLC activity in the PVN
to directly compare to the frontal cortex; due to the small size of the PVN. We have previously
reported that the neuroendocrine effects of DOI are mediated exclusively by activation of 5-
HT2A receptors (but not 5-HT2C receptors) in PVN (Zhang et al., 2002). Here, we found an
apparent dose-dependent inhibitory effect of AG490-pretreatment on 5-HT2A receptor
stimulated oxytocin and corticosterone plasma levels whereas ACTH levels were not affected.
There are other examples of dissociation of the regulation of hormone responses to 5-HT
receptor stimulation such as in oxytocin and ACTH responses to fluoxetine or estradiol
(D'Souza, et al., 2004;Damjanoska, et al., 2003). These results suggest that the JAK-STAT
signaling pathway could be involved in either the synthesis or release of these hormones.
Further experiments, studying the expression of JAK-STAT proteins in either oxytocin and/or
CRF containing cells of the PVN could shed light in the mechanisms by which JAK-STAT
dose-dependently regulate the 5-HT2A-mediated release of oxytocin and corticosterone.
Furthermore, differences in the relative levels of RGS7 and RGS4 in frontal cortex compared
to the PVN could also contribute to difference in the effects of the JAK-STAT inhibitor AG490
on the 5-HT2A receptor stimulated responses in these brain regions. Another possible difference
between the desensitization responses could be different PLC isoforms mediating the signaling
pathways.
In summary, this study demonstrates that olanzapine-induced desensitization of 5-HT2A
receptor-stimulated PLC signaling is dependent on increased expression of RGS7 protein via
activation of the JAK-STAT pathway in rat frontal cortex as was previously demonstrated in
a cortical cell line. However, olanzapine-induced desensitization of 5-HT2A receptors in
neuroendocrine cells appears to be independent of JAK-STAT, suggesting either regional
differences or differences in the regulation of pathways down-stream from 5-HT2A receptors
by atypical antipsychotics. Further studies are needed to determine the role of JAK-STAT
signaling pathway in the regulation of plasma hormone levels.
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Olanzapine treatment significantly increased (* p<0.05) phosphorylation of JAK2 in the frontal
cortex. AG490 treatment alone had no effect on phosphorylation of JAK2, however, inhibition
of the JAK-STAT pathway with AG490 pre-treatment significantly attenuated phosphorylation
of JAK2. Total JAK2 protein levels were not altered. (* indicate significantly different from
olanzapine treated rats p<0.05), whereas AG490 alone had no effect on JAK2 levels. There
were four animals in each treatment group and the western blots were repeated three times.
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PLC activity in the frontal cortex. (A): 5-HT-stimulated PLC activity in the frontal cortex is
significantly decreased with 7 days of daily olanzapine injections compared to vehicle-treated
control rats (*p < 0.01). AG490 injections alone had no effect on the PLC activity whereas the
olanzapine-induced decrease in PLC activity was significantly (*p<0.05) attenuated by pre-
injections of AG490 (10 mg/kg). (B) GTPγS-stimulated-PLC activity was not altered by either
the AG490 or olanzapine treatments. There were five animals used in each treatment group
and the assay was performed three times with two replicates.
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Olanzapine treatment significantly (* p<0.05) increased RGS7 mRNA in the frontal cortex (A)
and membrane-bound RGS7 protein levels (B) over vehicle-treated control rats. AG490 pre-
treatment completely blocked the olanzapine-induced increase in mRNA levels of RGS7.
Olanzapine-induced increases in protein levels were also blocked by AG490 pretreatment. (*
indicate significantly different from olanzapine treated rats p<0.05), whereas AG490 alone had
no effect on RGS7 levels. This assay was performed with four animals in each treatment group,
three separate times and each time in triplicate.
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Chronic treatment with olanzapine significantly attenuated DOI-stimulated hormone
responses. Oxytocin (A), ACTH (B) and corticosterone (C) responses to a challenge with DOI
1 mg/ml at 30 min post-injection. The data represent the mean ± S.E.M. of eight rats per group.
Basal plasma oxytocin, ACTH and corticosterone levels were not significantly different among
vehicle, AG490 and olanzapine injected rats. DOI-challenge induced a significant increase of
plasma oxytocin, ACTH and corticosterone levels compared with saline-challenge groups. A
significant difference amongst DOI-challenged control and treated rats is indicated by * for
p < 0.001. A significant effect of chronic olanzapine and AG490 treatment compared with
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vehicle treatment is indicated by δ δ, p < 0.01. There were eight animals in each treatment
group and each sample was examined in quadruplicate.
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Chronic olanzapine increased JAK2 phosphorylation in the PVN. The levels of phosphorylated
JAK2 were significantly increased by daily treatments of 10 mg/kg olanzapine (Olan). Total
JAK2 protein levels were not altered by olanzapine. *Indicates significantly different from
vehicle-treated control rats at p<0.001. There were four animals in each treatment group and
each western blot assay was performed three times.
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Chronic olanzapine treatment increased RGS7 protein levels in the PVN. RGS7 levels in the
membrane fraction of the PVN were increased by daily treatment with 10.0 mg/kg olanzapine.
Actin was used to verify equal loading of lanes in the SDS PAGE gel. *Indicates significantly
different from vehicle-treated control rats compared to 10 mg/kg olanzapine at p < 0.001. There
were four animals in each treatment group and each western blot assay was performed three
times.
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